Eyedentity 的AI赌注：眼镜店在专科医生之前发现葡萄膜黑色素瘤

做的是什么生意

Eyedentity builds an AI diagnostics platform that analyzes fundus images taken during routine eye examinations to flag suspicious lesions and advise opticians whether to refer a patient to specialist care; its first application targets uveal melanoma.

启动资金：€1.3M (SEK 15M) oversubscribed first round, led by Norrsken Launcher with Karolinska Institutet Innovation and a group of angel investors, announced 2026-08-20.

起因

Eyedentity was founded in 2025 in Stockholm by Gustav Stålhammar, an ocular oncologist at St. Erik Eye Hospital and professor at Karolinska Institutet, and Mats Holmström, a machine learning engineer who previously worked on automating cancer care at RaySearch Laboratories. They saw that uveal melanoma, the most common primary intraocular cancer in adults, can be hard to distinguish from benign lesions at an early stage - while opticians already image many eyes.

经过

The startup joined the Karolinska Institutet Innovation Incubator and pitched at its InvestorDay, where it first connected with Norrsken Launcher. In August 2026 it closed an oversubscribed €1.3M round led by Norrsken Launcher, with Karolinska Institutet Innovation and angels participating, and is testing its platform in a live pilot with Synologen, a network of independent opticians in Sweden.

结果

Live and pre-commercial as of 2026-09-02: Eyedentity is running its Synologen pilot and using the round to pursue regulatory approval for its first product, extend the platform to conditions such as diabetic retinopathy and glaucoma, and prepare for Nordic commercialization before expanding across Europe and the US.

可借鉴之处

罕见病产品也能有大众市场的切入点：通过眼镜店进行筛查，因为眼镜店已经在拍摄眼睛，使检测成为现有就诊的副产品。